IntroDuctIon
Human embryonic stem cells (hESCs) represent an unlimited source of cells instrumental in replacing damaged tissues. In particular, hESCs can differentiate into various subtypes of vascular cells such as endothelial cells (ECs) or smooth muscle cells (SMCs) [1] [2] [3] [4] , and can be potentially applied toward repair of ischemic tissues, engineering artificial blood vessels and heart valves, repair of blood vessels and vascularization of engineered tissues [1] [2] [3] 5, 6 . Vascularization of engineered tissues is fundamental for tissue survival, structural organization and acceptance after in vivo transplantation. Nonvascularized tissues engineered in vitro are typically too small in size ( < 1 mm) to allow for sufficient oxygen diffusion 7 . In addition, the mechanisms and molecular cues governing embryogenesis can be further elucidated through the study of in vitro hESC differentiation to ECs and SMCs. Although several reports describe the critical role played by specific growth factors and extracellular matrix components as well as by environmental conditions in the induction of vascular hESC differentiation 1, 6, 8, 9 , the complete signaling and regulatory mechanisms mediating such differentiation are still poorly understood. Likewise, a pure source of such cells can allow for experimental setups to study endothelial-SMC cross talk and its role in the formation of functional blood vessels during development. Similarly, analysis of vascular differentiation of hESCs may shed light on the pathogenesis of vascular diseases, as well as on the early developmental stages of organs including pancreas, kidney, liver and neural tissue, which are highly reliant on the presence of blood vessels 10, 11 . Drug screening represents an additional field that can benefit from increased hESC-derived vascular cell accessibility 12, 13 . hESCderived vascular cells can be isolated to unlimited numbers for high-throughput assays, shortening the timelines for identification of new therapeutics and reducing in vivo testing periods. To date, human tissue samples (biopsies) provide drug discovery protocols with the required vascular cells for research. However, these cells exhibit limited survival times in culture, are limited in number and present significant genetic variability, which affects their applicability in screening technologies 12 . In contrast, hESC-derived vascular cells may offer valuable advantages over primary human vascular cells in their reproducibility and wide range of available identification and evaluation assays.
Earlier studies focusing on the vascular potential of hESCs 6, 14 have identified multiple markers specific to progenitor or fully differentiated vascular cells. Some studies describe cells isolation from embryoid bodies (EBs) cultured in suspension for several days 1, 2 . Others induced hESC differentiation to vascular cells in cocultures with mouse embryonic fibroblasts (MEF), OP9, S17 or MS-5 feeder layers 15, 16 . In this protocol, we describe a methodology to isolate mature ECs (Fig. 1) or vascular progenitor cells (VPCs) that can then be induced to differentiate into endothelial or SMCs (Fig. 2) . Specific differentiation to either cell type occurs by spontaneous EB differentiation, cultured in suspension for a variable number of days ( Fig. 3 summarizes the method in a flow diagram). This differs from other methods 15, 16 as it does not require additional cell types (as co-culture or feeder cells) or additional growth factors for EB differentiation (although for VPCs growth factors are required at the last stage of endothelial or SMC differentiation).
The protocol below focuses on the induction of vascular differentiation of hESCs and not on hESC culturing required before this stage. The reader is encouraged to look over protocols for hESC maintenance published earlier in this journal 17, 18 . Typically, we culture hESCs on mitomycin-treated MEF feeder layers, and passage hESCs via mechanical or enzymatic colony disruption.
hESC-derived ECs
Herein we describe a highly efficient method, adapted from a methodology previously reported by the authors 2 , for the isolation of hESC-derived ECs which make up ~2% of the EBs from which Isolation, differentiation and characterization of vascular cells derived from human embryonic stem cells they are purified. hESC-derived ECs are isolated from 13-d-old EBs by fluorescent-activated cell sorting (FACS) separation of CD31 + cells. The ideal time for isolation was chosen by the period in which endothelial-specific genes and proteins are most highly expressed during hESC differentiation. Vascular markers such as CD31, CD34 and vascular endothelial cadherin (VE-cad) peak between days 13 and 15. EBs are then dissociated into single cells and CD31 + cells are isolated by FACS using anti-CD31 antibodies and then expanded in endothelial growth medium. The hESC-derived endothelial cells, isolated as described below, express endothelial markers, including CD31, VE-cad, von Willebrand factor (vWF) and N-cadherin (N-cad), and demonstrate Dil-labelled acetylated low-density lipoprotein (Dil-ac-LDL) uptake (Fig. 1) . In addition, after seeding these embryonic ECs on biodegradable synthetic scaffolds, their biofunctionality can be evaluated in severe combined immunodeficient (SCID) mice upon subcutaneous implantation of the cell-embedded scaffold. Immunohistochemical analysis of the retrieved implants demonstrated CD31 + microvessel, which contained mouse blood cells 2 .
hESC-VPCs
In the protocol below, we also describe the isolation of VPCs based on a recent methodology described by the authors and others 1, 16 . VPCs can differentiate to endothelial 1, 16 or SMCs 1 when using the appropriate media conditions. Vascular progenitor cells are isolated at earlier stages of EB differentiation (day 10), where CD34 serves as a specific cell marker. VPC SMC-differentiating capacity may serve as an important model in studying early regulatory effects of these cells on initial vascularization stages, with a specific focus on their role in vascular network growth, vascular permeability and blood flow.
Vascular progenitor cells can be isolated by magnetic-activated cell separation (MACS) from 10-d-old EBs, using anti-human CD34 antibodies, as this endothelial/hematopoietic marker is minimally expressed on undifferentiated hESCs but is upregulated in EB (Fig. 2) 
MaterIals

REAGENTS
REAGENT SETUP hESC line Grow hESCs on mitomycin C-inactivated MEF as described previously 17, 18 . Briefly, culture hESCs in ESC medium in a 5% CO 2 incubator at 37 °C. Change growth medium daily and passage cells using 1 mg ml − 1 collagenase every 5-6 d onto a fresh gelatin-coated mitomycin-inactivated MEF plate. MEF Prepare MEF as described before 19 . Briefly, remove embryos (E13) from a pregnant mouse, wash with PBS, mince and trypsinize to a single cell suspension. Grow MEF in DMEM supplemented with 10% (vol/vol) FBS, split a confluent culture to 1:3 ratio and freeze cells that are not needed immediately. For mitomycin-inactivation treatment, incubate MEF with DMEM containing mitomycin C (8 µg ml − 1 ) for 2-3 h, wash three times with PBS, remove cells using trypsin-EDTA and seed 1.6 × 10 6 cells per 100 mm plate coated with 0.1% gelatin. A day later, MEFs are ready to be used as a feeder layer for undifferentiated hESCs. hESC medium DMEM-F12 supplemented with 20% (vol/vol) KSR, 1 mM l-glutamine, 1% (vol/vol) nonessential amino acids, 0.1 mM β-mercaptoethanol and 4 ng ml − 1 bFGF. Store at 4 °C up to 2 weeks. EB medium Supplement 400 ml knockout DMEM with 100 ml FBS (or KSR), 2.5 ml l-glutamine, 1 ml β-mercaptoethanol, 5 ml nonessential amino acid solution and filter through a 0.2 µm filter. Store at 4 °C. The solution can be used up to 1 month. EC medium Add 250 µl VEGF solution to 50 ml EGM-2 (final concentration of VEGF is 50 ng ml − 1 ). Store at 4 °C up to 2 weeks. SMC medium Add 250 µl PDGF BB solution to 50 ml EGM-2 (final concentration of PDGF BB is 50 ng ml − 1 ). Store at 4 °C up to 2 weeks. Gelatin solution For a 0.1% (wt/vol) solution, dissolve 0.5 g gelatin in 500 ml milli-Q water. Sterilize by autoclaving for 30 min. Let the solution cool for 30 min before coating 24-well plates. For a 1% (wt/vol) gelatin solution, dissolve 5 g gelatin in 500 ml milli-Q water and prepare as for a 0.1% solution. Gelatin-coated 24-well plates Pipette 1 ml of gelatin solution to each well of a 24-well plate. Incubate at 37 °C for at least 1 h and up to 2 weeks. Aspirate excess gelatin solution before use. Collagenase type-IV solution Dissolve 100 mg collagenase in 50 ml DMEM. Filter the solution using a 50 ml filtration system and store at 4 °C. The solution can be used up to 2 weeks. Collagenase B solution Dissolve 0.15 U collagenase B per ml DMEM. Sterilize the solution by filtration (0.22 µm filter) and store at 4 °C. The solution can be used up to 2 weeks. bFGF solution Dissolve 100 mg BSA in 2 ml PBS to form a 5% (wt/vol) BSA solution. Filter (0.22 µm) the solution. Prepare a 0.1% (wt/vol) BSA solution by adding 0.1 ml of the 5% (wt/vol) BSA solution to 4.9 ml sterile PBS. Add 1 ml of the 0.1% (wt/vol) BSA solution to a vial containing 10 µg bFGF. Aliquot the bFGF-BSA solution into sterile eppendorfs (0.25 ml per vial) and store at − 20 °C up to 6 months. VEGF 165 solution Add 0.1 ml of a 5% (wt/vol) BSA solution to 4.9 ml sterile PBS to yield a 0.1% (wt/vol) BSA solution. Add 1 ml of the 0.1% (wt/vol) BSA solution to a vial containing 10 µg of VEGF 165 . Aliquot the VEGF solution into sterile eppendorfs (0.250 ml per vial) and store them in the freezer at − 20 °C up to 6 months. PDGF BB solution Prepare a 4 mM HCl solution by adding 1 ml HCl 1N to 249 ml H 2 O. Add 300 µl of a 5% (wt/vol) BSA solution to 2.7 ml 4 mM HCl. Filter the solution using a 0.22 µm filtration system. Add 1 ml of the filtered solution to a vial containing 10 µg PDGF BB . Aliquot the PDGF BB solution (0.250 ml aliquots) and store at − 20 °C. MACS buffer Dissolve 0.5 g BSA in 50 ml PBS. Dissolve 0.0744 g EDTA in 50 ml PBS. Mix the BSA and EDTA solutions and sterilize by filtration (0.22 µm filter).  crItIcal Prepare fresh solutions on the day of experiment. FACS buffer Add 5% (vol/vol) FBS and 1% (vol/vol) penstrep to PBS and filter (0.22 µm filter). Store at 4 °C up to 2 weeks. DNase solution Reconstitute lyophilized DNase (100 mg) in 10 ml double distilled, sterile water. Aliquot and store at − 20 °C up to 6 months. 3% PFA Dilute 10 ml 16% (wt/vol) PFA in 40 ml PBS. Aliquot and store at − 20 °C. hESC-derived VPCs using their isolation protocol (Step 3B), and between 5-10 EB petri dishes (10 cm diameter, total yielding between 1-2 ×10 7 cells) may be necessary to obtain 0.3-1 × 10 5 ECs using their isolation protocol (Step 3A).  crItIcal step Optimal maintenance and genetic stability of hESCs are best obtained between passages 30-50.  crItIcal step The collagenase treatment must be optimized for each batch, as specific enzyme activity may vary.
2|
Gently remove hESC colonies from MEF and transfer to a 15 ml Falcon tube (typically, two 10-cm petri dishes of hESCs per Falcon tube). Centrifuge the cell suspension at 200g for 3 min at room temperature. Aspirate the supernatant and resuspend the cells in 10 ml EB medium. Add the cell suspension to a low-adherence 10 cm petri dish and incubate cells in a CO 2 incubator. Change EB medium every 2-3 d.  crItIcal step MEF are often removed with the hESC colonies; however, most of the MEF die in the subsequent days of culture. ? trouBlesHootInG Isolation of vascular cells from eBs 3| Proceed with the isolation to specifically isolate hESC-ECs (option A) or hESC-VPCs (option B). The VPC and EC isolation protocol is summarized in a flow diagram in .
Steps 1-2: EB formation and culturing
Step 3, option A: EQUIPMENT SETUP FACS setup FACSAria equipped with FACSDiva software is used for cell analysis and sorting. Set FACS parameters: adjust forward scatter and side scatter to exclude cell aggregates and cell debris. Set 530-nm band pass filter for FITC detection, and 585 nm for PI detection. For sorting, adjust to low speed using a wide nozzle of 100 µm. Use control samples to determine appropriate settings and to identify the population to be sorted. Prepare the control samples identically to experiment sample (as described in PROCEDURE, Step 3A) aside from the following changes:
For isotype control-use anti-IgG1κ-FITC antibody (1: Step 2) from the petri dish to a 15 ml Falcon tube. Let the EBs settle in the tube before aspirating the medium. Add 2-3 ml collagenase B solution and incubate for 2 h in the CO 2 incubator, 37 °C.  crItIcal step Regularly agitate tube to maximize the contact and activity of collagenase B with EBs. (ii) Remove the tube from the incubator and centrifuge the cell suspension at 300g for 3 min at room temperature.
Aspirate supernatant and wash EBs with 5 ml PBS. Centrifuge cells at 300g for 3 min at room temperature and aspirate supernatant. Add 2 ml of cell dissociation solution and incubate at room temperature for 10 min while agitating regularly to maximize the dissociation effect. (iii) Remove the tube from the incubator and pipette colonies up and down using a 1,000 µl pipette.
 crItIcal step Improper single-cell isolation from EB colonies results in cell clumps that cannot be passed through the cell strainer in step (iv) below, resulting in a decreased cell yield. ) in 500 µl MACS buffer.  crItIcal step Cell clumps can clog the MACS column in step (viii) below. Therefore, cell suspension must be thoroughly pipetted up and down before its application to the MACS column. ? trouBlesHootInG (ix) Remove LS column from the separator and place it over a new collection tube. Pipette 5 ml MACS buffer onto the LS column. Immediately flush out fraction with the magnetically labeled cells by firmly applying the plunger supplied with the column. (x) Centrifuge the cell suspension at 300g for 5 min at 4 °C, resuspend the cell pellets in 500 µl MACS buffer and repeat steps (vii-ix) to receive a high purity cell fraction.  crItIcal step After two passages through the MACS columns, the purity of the cells is typically above 80%. However, flow cytometry is recommended for the evaluation of cell purity using an anti-CD34 monoclonal antibody recognizing a region other than that recognized by the beads used in step (v) (e.g., anti-human CD34 antibody clone AC136, commercially available through Miltenyi Biotec). In addition, all RNA samples must be adjusted to yield equal amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal standard. table 2 ). Then, incubate sections with streptavidin peroxidase and complete the staining with DAB Chromogen, which results in a brown-colored precipitate at the antigen site (all reagents are included in the kit).  pause poInt Stained sections can be stored at room temperature for 1-3 years. (ix) View sections using a phase-contrast microscope.
• tIMInG Steps 1 and 2, EB formation and culturing: 10-13 d
Step 3A, Isolation of hESC-ECs: 4-6 h (i-viii) and 3-5 weeks (ix-xiii)
Step 3B, Isolation of hESC-derived VPCs: 5 h (i-x) and 15-30 d (xi-xiv)
Step 4A, Immunostaining: 3-4 h
Step 4B, Gene expression analyses: 2 d
Step 4C, Flow cytometry analyses: 3 h
Step 4D, ac-LDL uptake: 5 h
Step 4E, Matrigel assay: 1-3 d
Step 4F, Contraction assay: 1 d
Step 4G, Transplantation into SCID mice: 10- 2 . In addition, immunostaining of these isolated cells showed expression of both CD31 and vWF (Fig. 1b) , as well as standard EC organization of the VE-cad, N-cad and vinculin junction molecules 2 . CD31 + cells isolated in this manner also demonstrated the endothelial biofunctional characteristics by efficiently incorporating ac-LDL as detected by fluorescence microscopy after incubation with Dil-ac-LDL (Fig. 1c) . Furthermore, these CD31 + ECs formed blood vessel-like structures both in vitro by Matrigel and in vivo in PLLA-PLGA scaffolds transplanted in SCID mice. These vessels anastomosed with the mouse vasculature 2 . Vascular progenitor cells represent 10% of the overall EB cell population cultured in suspension for 10 d. Upon MACS isolation, > 90% of the isolated VPCs express CD34 antigen. At this stage, CD34
+ cells co-express high levels of CD31 (~55%), α-SMA (~45%) and SSEA4 (~43%), moderate levels of KDR-Flk-1 (~16%) and low levels of the hematopoietic marker CD45 (~1%) 1 . The differentiation of 3.5 × 10 4 CD34 + cells cultured for three passages in EC medium yields ~1 × 10 6 ECs, whereas the same initial number of CD34 + cells grown in SMC medium for the same number of passages, yields ~4 × 10 6 cells. VPC-derived ECs are characterized by cobblestone-like cell morphology and express typical endothelial markers at gene or protein levels, such as CD31, CD34, KDR-Flk-1, VE-cad and vWF (Fig. 2) , and incorporate ac-LDL. In addition, these cells do not express the SM-MHC, SMα-22 or angiopoietin-1 SMC markers. In contrast, VPC-derived SMCs are characterized by a spindle-like shaped morphology, express the α-SMA, SM-MHC, calponin, caldesmon and SMα-22 SMC markers (Fig. 2) , and have the ability to contract and relax in response to addition of common pharmacological agents such as carbachol and atropine. However, in some cases VPC-derived SMCs express some endothelial markers including angiopoietin-2 and Tie2 (ref. 1) (see below). Subcutaneous transplantation of VPC-derived ECs alone or together with VPC-derived SMCs, in the dorsal region of nude mice, led to microvessel formation. Most of these microvessels were patent with empty lumens, whereas a small percentage (~5-6%) contained mouse RBCs 1 . α-SMA + cells formed small, independent tubules or surrounded human microvessels 1 . Although the ECs and SMCs obtained from this differentiation and expansion protocol may not be identical to mature endothelial and SMCs, they share many features with mature vascular cells. Their differences may stem from their embryonic source or incomplete stages of differentiation. For example, the endothelial-derived cells isolated at day 13-15 from EBs and expanded in vitro for six passages express similar levels of CD34 and Flk-1 to those detected in HUVEC, but not similar levels of CD31 (78% versus 98% in HUVEC) 2 . In addition, VPC-derived SMCs are not completely differentiated as demonstrated by low expression of CD31 (~5%) and CD34 (~1%) markers while also expressing Tie2 and angiopoietin-2 markers characteristic of ECs 1 . When comparing the two methods of EC isolations, both CD31 + -based and CD34 + -based isolations yielded EC populations with similar characteristics, as demonstrated by their typical endothelial cell morphology as well as expression of typical endothelial markers such as CD31, CD34, KDR-Flk-1, VE-cad and vWF ( Figs. 1 and 2) . Flow cytometry analyses revealed differences in the expression levels of some membranal endothelial markers: 98% of the ECs expended from CD34 + isolations expressed CD31 versus 78% from the CD31 + isolation, 65% of the ECs expended from CD34 + -isolated cells express CD34 versus 16% expressing CD34 in CD31 + -isolated cultures, and only 12% of the CD34 + -derived ECs expressed Flk1, whereas 19% of the CD31 + -isolated ECs expressed this protein. ECs originating from CD34 + isolations expressed similar levels of CD31 (98%) to those detected in HUVEC, although ECs derived from CD31 + isolations expressed similar levels of CD34 (~16%) and Flk-1 (~19%) to those detected in HUVEC 1, 2 . Effective incorporation of ac-LDL and formation of blood vessel-like structures both in vitro by Matrigel and in vivo by transplantation into immunodeficient mice 1,2 were used to determine EC functionality of both CD31 + and CD34 + -derived populations.
Despite similarities in their external markers, the two population groups were isolated at different yields, owing to their ratios in the initial EB cell population. Although CD34 + cells represent 10% of the total EB cell population on 10-d culture, CD31
+ cells represent only 2% of the cell population in 13-d old EBs. Therefore, five-fold more EBs would be required to reach the same number of isolated ECs when using the CD31 + -based isolation method when compared with the number required using CD34 + -based isolation. However, in the VPC protocol, VEGF is needed to differentiate the VPC to ECs. autHor contrIButIons All authors wrote this paper.
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